Cellectis S.A. (NASDAQ:CLLS) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Cellectis S.A. (NASDAQ:CLLS) has received a consensus rating of “Moderate Buy” from the six analysts that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, four have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among brokers that have covered the stock in the last year is $7.00.

A number of equities research analysts have recently commented on CLLS shares. Citizens Jmp restated a “market outperform” rating and set a $8.00 target price on shares of Cellectis in a research report on Tuesday, April 14th. Weiss Ratings restated a “sell (d-)” rating on shares of Cellectis in a research report on Monday, April 20th. Barclays started coverage on Cellectis in a research report on Thursday. They set an “overweight” rating and a $9.00 target price on the stock. Finally, Jefferies Financial Group started coverage on Cellectis in a research report on Tuesday, February 17th. They set a “buy” rating and a $7.00 target price on the stock.

Institutional Investors Weigh In On Cellectis

Several institutional investors have recently bought and sold shares of CLLS. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Cellectis by 228.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,722,664 shares of the biotechnology company’s stock worth $5,856,000 after buying an additional 3,284,409 shares during the last quarter. Acadian Asset Management LLC boosted its holdings in Cellectis by 132.9% in the 1st quarter. Acadian Asset Management LLC now owns 46,377 shares of the biotechnology company’s stock worth $55,000 after buying an additional 26,461 shares during the last quarter. Delaney Dennis R acquired a new stake in Cellectis in the 3rd quarter worth about $68,000. B Group Inc. boosted its holdings in Cellectis by 0.8% in the 3rd quarter. B Group Inc. now owns 3,281,501 shares of the biotechnology company’s stock worth $9,352,000 after buying an additional 25,000 shares during the last quarter. Finally, Virtu Financial LLC acquired a new stake in Cellectis in the 3rd quarter worth about $72,000. 63.90% of the stock is currently owned by institutional investors and hedge funds.

Cellectis Price Performance

Shares of CLLS opened at $3.63 on Thursday. The business’s 50-day moving average is $3.70 and its two-hundred day moving average is $4.03. The company has a market capitalization of $364.23 million, a P/E ratio of -5.42 and a beta of 2.94. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.52 and a current ratio of 1.52. Cellectis has a fifty-two week low of $1.33 and a fifty-two week high of $5.48.

Cellectis (NASDAQ:CLLS) last posted its earnings results on Monday, May 11th. The biotechnology company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.08. Cellectis had a negative return on equity of 80.66% and a negative net margin of 89.51%.The firm had revenue of $7.55 million for the quarter, compared to analysts’ expectations of $11.04 million.

About Cellectis

Cellectis is a clinical‐stage biopharmaceutical company specializing in the development of gene‐edited cell therapies for oncology. Founded in 1999 and headquartered in Paris, France, the company also maintains operations in New York City and Raleigh, North Carolina. Cellectis applies its proprietary TALEN genome editing platform to engineer allogeneic chimeric antigen receptor T‐cell (CAR‐T) candidates designed to target blood cancers and solid tumors.

The company’s core business activities encompass the discovery, development and manufacturing of off‐the‐shelf immunotherapies.